Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.
Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.
Despite the initial shock of the COVID-19 pandemic, 2020 was a standout year for biopharma. The top 600 biopharma companies added $487bn in market capitalisation, and smaller biotechs saw a record-breaking $12.8bn raised by IPO and $20bn invested by venture financers.
Fortunes in the medical device industry were more divided. Companies developing diagnostics and treatments benefitted from the continued focus on COVID-19, but other segments suffered from decreased demand, and this trend could continue into 2021.
Report Highlights — Pharma & Biotech:
Report Highlights — Medtech:
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.
Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.
Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.
Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.
Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.
Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.
Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.
Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.
Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit.
 |
 |
 |
|
|---|---|---|---|
| Stimulus | |||
| Daily news with expert analysis |  |
|
|
| Interviews with industry leaders | |
|
|
| Company & product events coverage | |
|
|
| Response | |||
| Consensus forecasts to 2024 |  |
|
|
| Archived consensus forecasts | |
|
|
| Sales by indication | |
|
|
| Therapy area, mechanism of action, and other classifications | |
|
|
| Licensing deals, M&A, venture financing and IPOs | |
|
|
| Orphan drugs and biosimilars analysis | |
|
|
| Success rate benchmarks (PTRS) |  |
||
| Time-in-phase benchmarks by indication | |
||
| Comprehensive product and trial level R&D costs | |
||
| Clinical trials design and outcomes | |
||
| Net Present Value calculator | |
||
| Calendar of market events and catalysts | |